Biological Warfare from China ... Round 2

Biological Warfare from China ... Round 2

Radioactive with Steve Mitton

Feb 15, 2022

Highlights from this show:

'Palin judge deliberately tainted verdict': Legal experts slam Clinton-appointed judge for tossing out Sarah Palin's NYTimes libel case while the jury is STILL deliberating on it

While jurors have been warned to avoid reporting of the case until they've concluded their task, experts say it's inevitable that news of its dismissal will reach them, and potentially undermine their efforts to reach an honest, unprejudiced verdict which no longer carries any weight.

'We've known how to cure COVID since about March of 2020': Dr. Robert Malone

The sudden scramble two years later by Democratic governors to lift mask mandates "is a clear pivot consequent to their horrible polling numbers," Malone said. "It's exactly what I predicted when people were asking me, 'How will we know when this thing is over?' I've said, 'Well, you'll know it because they'll all start giving awards to each other and claiming that they're the ones that are responsible for curing it.'"

Swamp Thing: Who is Colin Kahl?

Kahl has since gotten himself a perch at the U.S. Department of Defense, in the number-three post. He has the same smug, smarmy expression on his face as his BFF, former Obama administration national security deputy secretary Ben Rhodes, a creative writing major who ended up in the national security establishment, too, and whose real value to Obama was in his capacity for lies and domestic political dirty tricks:

Trudeau’s State Media Labels ‘Freedom’ A “Far Right” Concept

Anker states “On the far right, [individual freedom] is often translated into somebody who refuses to be bound by norms of equality, treating all people equally or norms to remedy inequality, whether that’s trying to remedy racial discrimination or gender discrimination.”

Daratumumab

Daratumumab, sold under the brand name Darzalex, is an anti-cancer monoclonal antibody medication. It binds to CD38,[2] which is overexpressed in multiple myeloma cells.[3] Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.